Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.

Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M.

Nat Med. 2019 May;25(5):861. doi: 10.1038/s41591-019-0433-3.

PMID:
30918364
2.

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.

Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M.

Nat Med. 2019 Apr;25(4):620-627. doi: 10.1038/s41591-019-0367-9. Epub 2019 Mar 4. Erratum in: Nat Med. 2019 Mar 27;:.

3.

Lipopolysaccharide endotoxemia induces amyloid-β and p-tau formation in the rat brain.

Wang LM, Wu Q, Kirk RA, Horn KP, Ebada Salem AH, Hoffman JM, Yap JT, Sonnen JA, Towner RA, Bozza FA, Rodrigues RS, Morton KA.

Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):86-99. eCollection 2018.

4.

Correlation of Glioma Proliferation and Hypoxia by Luciferase, Magnetic Resonance, and Positron Emission Tomography Imaging.

Karsy M, Gillespie DL, Horn KP, Burrell LD, Yap JT, Jensen RL.

Methods Mol Biol. 2018;1742:301-320. doi: 10.1007/978-1-4939-7665-2_26.

PMID:
29330810
5.

The Influential Role of BCL2 Family Members in Synovial Sarcomagenesis.

Barrott JJ, Zhu JF, Smith-Fry K, Susko AM, Nollner D, Burrell LD, Pozner A, Capecchi MR, Yap JT, Cannon-Albright LA, Deng X, Jones KB.

Mol Cancer Res. 2017 Dec;15(12):1733-1740. doi: 10.1158/1541-7786.MCR-17-0315. Epub 2017 Aug 29.

6.

Method for detecting voxelwise changes in fluorodeoxyglucose-positron emission tomography brain images via background adjustment in cancer clinical trials.

Qin L, Schwartzman A, McCall K, Kachouie NN, Yap JT.

J Med Imaging (Bellingham). 2017 Apr;4(2):024006. doi: 10.1117/1.JMI.4.2.024006. Epub 2017 Jun 1.

7.

Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.

O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT.

J Neurooncol. 2016 Dec;130(3):495-503. Epub 2016 Aug 30.

PMID:
27576699
8.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.

Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.

9.

FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.

Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM.

Cancer Imaging. 2015 Sep 3;15:15. doi: 10.1186/s40644-015-0049-x.

10.

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD.

J Clin Oncol. 2015 Aug 20;33(24):2623-31. doi: 10.1200/JCO.2014.60.0353. Epub 2015 Jul 13.

11.

Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.

Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman GS.

J Nucl Med. 2015 Jun;56(6):955-61. doi: 10.2967/jnumed.115.158402. Epub 2015 Apr 16.

12.

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.

Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD.

Cancer Imaging. 2014 Nov 12;14:30. doi: 10.1186/s40644-014-0030-0.

13.

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME.

Clin Genitourin Cancer. 2015 Apr;13(2):113-23. doi: 10.1016/j.clgc.2014.08.007. Epub 2014 Oct 22.

14.

Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology.

Guo M, Yap JT, Van den Abbeele AD, Lin NU, Schwartzman A.

Stat. 2014 Jan 1;3(1):172-186.

15.

Bevacizumab plus ipilimumab in patients with metastatic melanoma.

Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D.

Cancer Immunol Res. 2014 Jul;2(7):632-42. doi: 10.1158/2326-6066.CIR-14-0053. Epub 2014 Apr 21. Erratum in: Cancer Immunol Res. 2014 Sep;2(9):923.

16.

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL.

J Clin Oncol. 2014 Apr 20;32(12):1202-9. doi: 10.1200/JCO.2013.54.0518. Epub 2014 Mar 24.

17.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.

J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.

18.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.

J Clin Oncol. 2012 Jul 1;30(19):2401-7. doi: 10.1200/JCO.2011.39.9394. Epub 2012 May 21.

19.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI.

Blood. 2012 May 17;119(20):4597-607. doi: 10.1182/blood-2011-10-388298. Epub 2012 Mar 1.

20.

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.

Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA.

J Nucl Med. 2012 Apr;53(4):567-74. doi: 10.2967/jnumed.111.094425. Epub 2012 Mar 1.

21.

Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.

Aristophanous M, Yong Y, Yap JT, Killoran JH, Allen AM, Berbeco RI, Chen AB.

Radiother Oncol. 2012 Mar;102(3):377-82. doi: 10.1016/j.radonc.2011.12.015. Epub 2012 Jan 20.

PMID:
22265731
22.

Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning.

Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e99-105. doi: 10.1016/j.ijrobp.2010.12.060. Epub 2011 Mar 4.

PMID:
21377285
23.

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.

Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE.

Acad Radiol. 2011 Jan;18(1):54-62. doi: 10.1016/j.acra.2010.08.021. Epub 2010 Oct 30.

24.

Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions.

Aristophanous M, Yap JT, Killoran JH, Chen AB, Berbeco RI.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):900-8. doi: 10.1016/j.ijrobp.2010.08.028. Epub 2010 Oct 13.

PMID:
20950956
25.

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.

Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD.

AJR Am J Roentgenol. 2010 Sep;195(3):W221-8. doi: 10.2214/AJR.09.3928.

26.

Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial.

Otero HJ, Yap JT, Patak MA, Erturk SM, Israel DA, Johnston CJ, Sakellis C, Rybicki FJ, Van den Abbeele AD, Ros PR.

AJR Am J Roentgenol. 2009 Aug;193(2):326-32. doi: 10.2214/AJR.08.1565.

PMID:
19620427
27.

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML.

J Clin Oncol. 2009 Jul 1;27(19):3154-60. doi: 10.1200/JCO.2008.20.9890. Epub 2009 May 18.

28.

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC.

Clin Cancer Res. 2008 Apr 15;14(8):2387-95. doi: 10.1158/1078-0432.CCR-07-1430.

29.

Image-guided cancer therapy using PET/CT.

Yap JT, Carney JP, Hall NC, Townsend DW.

Cancer J. 2004 Jul-Aug;10(4):221-33. Review.

PMID:
15383203
30.

PET/CT today and tomorrow.

Townsend DW, Carney JP, Yap JT, Hall NC.

J Nucl Med. 2004 Jan;45 Suppl 1:4S-14S. Review.

31.

Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.

Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL.

Br J Cancer. 2003 Jul 21;89(2):262-7.

32.

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.

Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM.

J Clin Oncol. 2003 Aug 1;21(15):2823-30. Epub 2003 Jun 13.

PMID:
12807935
33.

A general method to correct PET data for tissue metabolites using a dual-scan approach.

Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, Cunningham VJ.

J Nucl Med. 2000 Apr;41(4):706-11.

34.

On-line measurement of exhaled [11C]CO2 during PET.

Gunn RN, Ranicar A, Yap JT, Wells P, Osman S, Jones T, Cunningham VJ.

J Nucl Med. 2000 Apr;41(4):605-11.

35.

Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET.

Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG.

J Nucl Med. 1999 Nov;40(11):1848-56.

36.

Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram.

Kao CM, Yap JT, Mukherjee J, Wernick MN.

IEEE Trans Med Imaging. 1997 Dec;16(6):738-49.

PMID:
9533575

Supplemental Content

Support Center